Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial

L. Vanderbeke, N.A.F. Janssen, D.C.J.J. Bergmans, M. Bourgeois, J.B. Buil, Y. Debaveye, P. Depuydt, S. Feys, G. Hermans, O. Hoiting, B. van der Hoven, C. Jacobs, K. Lagrou, V. Lemiale, P. Lormans, J. Maertens, P. Meersseman, B. Megarbane, S. Nseir, J.A.H. van OersM. Reynders, B.J.A. Rijnders, J.A. Schouten, I. Spriet, K. Thevissen, A.W. Thille, R. Van Daele, F.L. van de Veerdonk, P.E. Verweij, A. Wilmer, R.J.M. Bruggemann, J. Wauters*, Dutch Belgian Mycosis Study Grp

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

7 Citations (Web of Science)
Original languageEnglish
Pages (from-to)674-686
Number of pages13
JournalIntensive Care Medicine
Volume47
Issue number6
DOIs
Publication statusPublished - 1 Jun 2021

Keywords

  • Aspergillosis
  • Influenza
  • Posaconazole
  • Critical illness
  • Prophylaxis
  • AZOLE RESISTANCE
  • PROPHYLAXIS
  • SURVEILLANCE
  • FLUCONAZOLE
  • FUMIGATUS
  • VIRUS

Cite this